Hepatorenal Syndrome Treatment Market Size to Exceed $19.94 Billion by 2029 | Growth and Industry Trends
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Hepatorenal Syndrome Treatment Market Grown from 2024 to 2025?
There has been robust growth in the market size for the treatment of hepatorenal syndrome in recent years. The market is projected to increase from $14.49 billion in 2024 to $15.31 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. Factors contributing to growth during the historic period include expansion of the automotive industry, needs of the aerospace sector, benefits from material usage, enhancement in mechanical properties, rigorous industry regulations, as well as improvements in efficiency and precision.
What Growth Rate Is Anticipated for the Hepatorenal Syndrome Treatment Market in the Coming Years?
Expectations are high for significant expansion in the hepatorenal syndrome treatment market over the next several years. Market growth is predicted to stretch to $19.94 billion by 2029, with a compound annual growth rate (CAGR) set at 6.8%. The anticipated growth over the forecast period could be due to the surge in renewable energy projects, the increasing demand for high-performance alloys, the focus on eco-friendly manufacturing, the extension of oil and gas exploration, and the required demand for superior performance components. Key trends for the forecast period encompass the integration of 4.0 industrial technologies, fresh research and development in the forging industry, customization for unique applications, increased automation in forging processes, and breakthroughs in heating and cooling technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10414&type=smp
Who Are the Leading Companies in the Hepatorenal Syndrome Treatment Market?
Major companies operating in the hepatorenal syndrome treatment market include BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC, Baxter International Inc., La Jolla Pharmaceutical Company, Noorik Biopharmaceuticals AG, Novartis AG, Zydus Lifesciences Limited, Ocelot Bio Inc., New Medicon Pharma Lab Private Limited, Arrowhead Pharmaceuticals, Stealth BioTherapeutics Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Catalyst Pharmaceuticals Inc., Bayer AG, Gilead Sciences Inc.
What Are the Key Drivers of the Hepatorenal Syndrome Treatment Market?
The hike in the reported cases of liver damage or cirrhosis is projected to push forward the hepatorenal syndrome treatment market’s growth. Cirrhosis, a critical liver disease, characterizes the perpetual replacement of healthy liver tissue with scar tissue. The goal of hepatorenal syndrome treatment is to preserve kidney function in patients while also reducing the symptoms and detrimental effects of the disorder. As a result, these strategies can potentially improve overall health, making the patient a more suited candidate for liver transplant surgery. For example, data released by the British Liver Trust, a charity organization based in the UK, in July 2023 indicated a 22% increase in hospital admissions due to liver disease in England over a single year. The total escalated from 67,458 in 2021 to 82,290 in the financial year 2022. Therefore, this surge in liver damage or cirrhosis incidences is bolstering the hepatorenal syndrome treatment market’s growth.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10414&type=smp
What Are the Key Market Segments in the Hepatorenal Syndrome Treatment Industry?
The hepatorenal syndrome treatment market covered in this report is segmented –
1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome
2) By Treatment: Therapeutics, Surgical Treatment
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Type 1 Hepatorenal Syndrome: Intravenous Albumin, Vasopressors, Dialysis, Liver Transplantation
2) By Type 2 Hepatorenal Syndrome: Albumin Infusion, Midodrine, Octreotide, Liver Transplantation
What Are the Latest Trends in the Hepatorenal Syndrome Treatment Market?
The upward trend in research and development activities aimed at hepatorenal syndrome treatment is gaining momentum in the market for the same. To maintain their standing in the market, firms involved in hepatorenal syndrome treatment are devoting more attention to research and development. An example of this is Mallinckrodt Pharmaceuticals, a specialty product and treatment developing, manufacturing, and distributing company based in Ireland, which in September 2022, received the FDA’s consent for Terlivaz, an injection to improve kidney function in adults suffering from hepatorenal syndrome. The FDA’s endorsement was significantly influenced by the Phase 3 CONFIRM trial- the largest-ever prospective research (n=300) conducted to assess terlipressin’s safety and efficacy in patients with HRS type 1 (HRS-1) in the U.S. and Canada. The CONFIRM trial’s primary objective, Verified HRS Reversal, which pertains to the improvement in renal function, the elimination of the requirement for dialysis, and short-term existence, was accomplished (p=0.012).
Access The Full Report Here:
What Are the Key Regional Markets in the Hepatorenal Syndrome Treatment Industry?
North America was the largest region in the hepatorenal syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global hepatorenal syndrome treatment market during the forecast period. The regions covered in the hepatorenal syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10414
This Report Delivers Insight On:
1. How big is the hepatorenal syndrome treatment market, and how is it changing globally?
2. Who are the major companies in the hepatorenal syndrome treatment market, and how are they performing?
3. What are the key opportunities and risks in the hepatorenal syndrome treatment market right now?
4. Which products or customer segments are growing the most in the hepatorenal syndrome treatment market?
5. What factors are helping or slowing down the growth of the hepatorenal syndrome treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
